Economic evaluation of olmesartan/amlodipine fixed-dose combination for hypertension treatment in China.
CONCLUSIONS: Olmesartan/amlodipine fixed-dose combination confers better health outcomes and costs less compared with olmesartan and amlodipine free combination and valsartan/amlodipine fixed-dose combination and is cost-effective compared with amlodipine for hypertension treatment in China.
PMID: 31782677 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Cardiology | Cardiovascular | China Health | Databases & Libraries | Diovan | Economics | Epidemiology | Exforge | Health Management | Heart | Hypertension | Norvasc